Polo-like kinase inhibitors in hematologic malignancies.

  title={Polo-like kinase inhibitors in hematologic malignancies.},
  author={Chetasi Talati and Elizabeth A. Griffiths and Meir Wetzler and Eunice S. Wang},
  journal={Critical reviews in oncology/hematology},
Polo-like kinases (Plk) are key regulators of the cell cycle and multiple aspects of mitosis. Two agents that inhibit the Plk signaling pathway have shown promising activity in patients with hematologic malignancies and are currently in phase III trials. Volasertib is a Plk inhibitor under evaluation combined with low-dose cytarabine in older patients with acute myeloid leukemia (AML) ineligible for intensive induction therapy. Rigosertib, a dual inhibitor of the Plk and phosphatidylinositol 3… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
9 Citations
0 References
Similar Papers


Publications citing this paper.
Showing 1-9 of 9 extracted citations

Similar Papers

Loading similar papers…